Litigation Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)
✉ Email this page to a colleague
AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)
Docket | ⤷ Sign Up | Date Filed | 2023-11-20 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | |
Jury Demand | None | Referred To | |
Parties | ABBVIE INC. | ||
Patents | 10,519,164; 8,962,629; 9,951,080; 9,963,459; RE47,221 | ||
Attorneys | Jack B. Blumenfeld | ||
Firms | Morris, Nichols, Arsht & Tunnell | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in AbbVie Inc. v. Hetero USA, Inc.
Biologic Drugs cited in AbbVie Inc. v. Hetero USA, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2023-11-20 | 1 | Complaint | 393 Patent”); 10,519,164 (“the ’164 Patent”); 10,730,883 (“the ’883 Patent”); 10,981,924 (“the ’924 Patent… United States Patent Nos. RE47,221 (“the RE’221 Patent”); 8,962,629 (“the ’629 Patent”); 9,951,080 (… (“the ’080 Patent”); 10,981,923 (“the ’923 Patent”); 11,186,584 (“the ’584 Patent”); 11,661,425 (“the…the ’425 Patent”); 11,680,069 (“the ’069 Patent”); 11,718,627 (“the ’627 Patent”); 11,198,697 (“the ’… ’697 Patent”); 9,963,459 (“the ’459 Patent”); 10,344,036 (“the ’036 Patent”); 10,202,393 (“the ’393 | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |